Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$8.46-1.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.65 → 0.05 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for HBIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted gross margin between 58% and 60% in fiscal year 2026 | It targets a gross margin near 58% to 60%. | Broken | Gross margin falls below 58% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Third Quarter 2026 Guidance The Company’s third quarter outlook reflects expected mid-single-digit year-over-year revenue growth at the midpoint of guidance, driven by expected ongoing demand across CMT and new product innovation (NPI) platforms and improving year-over-year profitability on an adjusted EBITDA basis.” ““We are seeing solid commercial traction across our telemetry and cellular and molecular technology (CMT) products, driven by our AAA and electroporation businesses, and strong engagement from researchers utilizing our preclinical platform.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
HBIO is a high-risk, loss-making business with recent financial performance in the top half of its industry and a supportive Healthcare sector backdrop. Its multi-year view is intact, but management has been volatile and recent earnings results have been uneven.
The valuation evidence is mixed: one measure says HBIO is cheap versus peers, while another shows an 18% premium, and model confidence is low. The priced-in assessment is tagged as justified, with a negative expectations gap, but the evidence does not establish exactly what the market assumes.
Near term, management is on track with its 2026 revenue and adjusted gross margin goals, while adjusted EBITDA grew only slightly in the first half. The company remains loss-making, and the next report carries meaningful risk given its recent misses and a 45% estimated miss probability. For the multi-year thesis, continued revenue growth and margin delivery matter more than the improving sector backdrop alone.
A guidance cut at the next call would weaken the thesis, while further weakening in jobs data could add pressure to cyclical Healthcare names. Continued earnings strength and higher guidance from sector bellwethers such as ISRG, BDX, and RMD would support the sector backdrop. The key test is whether HBIO sustains its stated growth and margin goals despite its uneven earnings record.
The 1-to-3-year view remains intact, supported by improving recent results and a Healthcare sector tailwind, but losses and execution risk leave the thesis fragile around upcoming results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Progress on Project Viking manufacturing consolidation | A supporting condition in Harvard Bioscience Inc's published investment case. The stated target is 50% progress on Project Viking by mid-2026. | Intact | Progress stalls below 50% by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of 2% to 4% in fiscal year 2026 | A primary condition in Harvard Bioscience Inc's published investment case. The stated target is >=2% and <=4% growth in 2026. | Improving | Revenue growth falls below 2% in FY26 | Revenue growth: 11.13% FY2026-Q2; GAAP. Published target: >=2% and <=4% growth in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 202611.134474 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.44 → $0.05 · observed estimates
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-25 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-26 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-27 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-28 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-29 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-30 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-07-31 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-01 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-02 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-03 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-04 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-05 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-06 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-07 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-08 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-09 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-10 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-12 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-13 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-14 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-15 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-16 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-17 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-18 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-19 | $0.44 | $94,200,000 | 2 / 2 |
| 2026-08-20 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-21 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-22 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-23 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-24 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-25 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-26 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-27 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-28 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-29 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-30 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-08-31 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-01 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-02 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-03 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-04 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-05 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-06 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-07 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-08 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-09 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-10 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-11 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-12 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-13 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-14 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-15 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-16 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-17 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-18 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-19 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-20 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-21 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-22 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-23 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-24 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-25 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-26 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-27 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-28 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-29 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-09-30 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-01 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-02 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-03 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-04 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-05 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-06 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-07 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-08 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-09 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-10 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-11 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-12 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-13 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-14 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-15 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-16 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-17 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-18 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-19 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-20 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-21 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-22 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-23 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-24 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-25 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-26 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-27 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-28 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-29 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-30 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-10-31 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-11-01 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-11-02 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-11-03 | $0.65 | $94,550,000 | 2 / 2 |
| 2026-11-04 | $0.05 | $94,700,000 | 2 / 3 |
| 2026-11-05 | $0.05 | $94,700,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.